Artis Ventures (AV)

Artis Ventures (AV) is a San Francisco-based venture capital firm renowned for its specialized focus on "TechBio," a unique investment thesis at the intersection of technology and biology. The firm actively seeks to identify and back category-defining companies that leverage deep technological innovation to drive scientific breakthroughs and transform industries. AV primarily targets early-stage opportunities, often taking a lead or co-lead position in Seed and Series A funding rounds, demonstrating a commitment to foundational company building.

The firm has successfully raised substantial capital, underscoring its capacity to support ambitious ventures. Their most recent fund, Artis Ventures V, closed at $200 million in 2021, following their $180 million Artis Ventures IV fund in 2018. This significant capital base allows AV to provide robust financial backing to its portfolio companies. Beyond capital, Artis Ventures emphasizes a partnership approach, working closely with founders to navigate the complexities of scaling disruptive technologies in highly regulated and scientific domains.

Artis Ventures' investment strategy is characterized by a long-term view, aiming to build enduring companies that can reshape markets. They are known for their rigorous due diligence and a hands-on approach to supporting portfolio companies through strategic guidance and network access. While their typical initial check size ranges from $5 million to $10 million, they possess the flexibility and capital reserves to participate in larger follow-on rounds as their portfolio companies achieve key milestones and scale. Their deep expertise in both technology and life sciences positions them as a strategic partner for innovators in the burgeoning TechBio sector.